MedTrace Logo

Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency

NCT05410093 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-06-08

No results posted yet for this study

Summary

Resveratrol is a natural plant antitoxin widely found in grapes, mulberries, and other plants. Resveratrol mediates a variety of pharmacological effects, including antioxidant, immunomodulatory, anti-inflammatory, and anti-apoptotic, and plays a protective and therapeutic role in the development of several ROS-related diseases, including POI/POF.

Conditions

  • Primary Ovarian Insufficiency

Interventions

DRUG

Resveratrol

Take Resveratrol (250mg, NuMedica, FDA approved) at a dose of 250mg per day for three months

DRUG

Vitamin E

Take vitamin E at a dose of 100 mg per day for three months

Sponsors & Collaborators

  • Affiliated Hospital of Nantong University

    lead OTHER

Principal Investigators

  • wang xia, Master · Hospital affiliated of nantong university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05410093 on ClinicalTrials.gov